In the context of HER2-positive breast cancer, the Adjuvant Paclitaxel and Trastuzumab trial has demonstrated the efficacy of a de-escalated regimen of TH (paclitaxel and trastuzumab) for 12 cycles in achieving excellent outcomes for lower-risk patients [10]. Here, ERBB2 is linked to breast carcinoma.